Global Engineering Services Industry Market Research Report Now Available from IBISWorld


Los Angeles, CA (PRWEB) April 22, 2012

The global market for engineering services consists of the work performed by consultant engineering firms along with the in-house services undertaken by construction contractors, manufacturers, government agencies and utility owners. According to IBISWorld industry analyst Anthony Kelly, the industry’s performance is principally driven by the trends into construction, manufacturing and mining developments (particularly in the large industrial economies) and increasingly from work in the fields of technological development and the sustainable environment. Over the past decade the industry has expanded its operations by broadening across a wider range of multidisciplinary services, by the trend towards globalization and through the outsourcing of services by public authorities and major corporations.

The Global Engineering Services industry is one of the largest professional service industries, generating revenue of about $ 530 billion in 2012 (up 3.0% on the previous year), and employing 2.9 million people. Industry value added currently totals $ 318 billion, or 0.6% of the world’s GDP, two-thirds of which represents payments to employees and the balance the industry’s operating profit. The industry’s performance deteriorated during the late 2000s with the onset of recession in several of the largest developed economies and the subsequent decline in construction and industrial production. Despite the current improvement, industry revenue is estimated to average subdued growth by 0.5% per annum over the five years through 2012.

?International trade represents a significant share of industry activity (10.6% of revenue in 2012) and is mainly confined to relatively few large-scale consulting engineering firms that are capable of operating outside national boundaries,? said Kelly. A feature of the industry that has accompanied globalization has been the amalgamation of the larger players to achieve scale economies, broaden the market and strengthen the human and financial resources (consistent with the trend evident in other knowledge-based industries such as accounting, law, advertising and architecture).

The Global Engineering Services industry has a low concentration of ownership, with the four largest companies accounting for about 6.0% of annual industry revenue. The largest players in the global market for engineering services include URS Corporation, SNC-Lavalin Group, Bechtel Group, Jacobs Engineering Group, Fluor Corporation, AECOM Technology Corporation, CH2M HILL Companies, WS Atkins plc, and Altran Technologies. Despite this low concentration, there has been a trend over the past decade for the consolidation of the operations of many of the world’s leading consulting engineering firms, through mergers or strategic alliances. These large-scale, multidisciplined, multinational companies are well placed to win contracts in most markets. For more information, visit IBISWorld?s Global Engineering Services in the US industry report page.

Follow IBISWorld on Twitter: https://twitter.com/#!/IBISWorld

Friend IBISWorld on Facebook: http://www.facebook.com/pages/IBISWorld/121347533189

IBISWorld industry Report Key Topics

The industry comprises establishments engaged in applying physical laws and principles of engineering in the design, development and use of machines, materials, instruments, structures, processes and systems. The assignments may involve the provision of advice, preparation of feasibility studies, preparation of preliminary and final plans and designs, the provision of technical services on construction and project evaluation.

Industry Performance

Executive Summary

Key External Drivers

Current Performance

Industry Outlook

Industry Life Cycle

Products & Markets

Supply Chain

Products & Services

Major Markets

Globalization & Trade

Business Locations

Competitive Landscape

Market Share Concentration

Key Success Factors

Cost Structure Benchmarks

Barriers to Entry

Major Companies

Operating Conditions

Capital Intensity

Key Statistics

Industry Data

Annual Change

Key Ratios

About IBISWorld Inc.

Recognized as the nation?s most trusted independent source of industry and market research, IBISWorld offers a comprehensive database of unique information and analysis on every US industry. With an extensive online portfolio, valued for its depth and scope, the company equips clients with the insight necessary to make better business decisions. Headquartered in Los Angeles, IBISWorld serves a range of business, professional service and government organizations through more than 10 locations worldwide. For more information, visit http://www.ibisworld.com or call 1-800-330-3772.







Related Wellness Press Releases

Two UCSF Scientists to Receive Prestigious Dementia Research Honor


San Francisco, CA (Vocus) February 19, 2010

Two UCSF scientists have been selected for the American Academy of Neurology?s prestigious Potamkin Prize, for their ?outstanding achievements? in research on dementias.

Bruce Miller, MD, W. & Mary Margaret Clausen Distinguished Professor of Neurology, and Lennart Mucke, MD, Joseph B. Martin Distinguished Professor of Neuroscience and director of the Gladstone Institute of Neurological Disease, will receive the honor for their major contributions to the understanding of the causes of, and treatment strategies for, frontotemporal lobar degeneration, Alzheimer?s disease and related diseases.

They will receive the prize on April 15, 2010 at the AAN?s annual meeting. The $ 100,000 prize is to be used for continuing research on dementias.

As director of UCSF?s Memory and Aging Center, Miller oversees a program that provides clinical care and conducts clinical research on all forms of dementia. The Center carries out neuroimaging studies aimed at improving diagnoses of the various forms of dementia, understanding the progression of the diseases and studying the impact of experimental drugs on the conditions. For more than a decade, he and Mucke, a basic researcher based at the Gladstone Institutes, have worked closely to build one of the premier dementia research programs in the world.

Miller has a special interest in the behavioral effects of dementia, notably those seen in FTLD, once commonly known as Pick?s disease. Along with Alzheimer?s disease, FTLD is the leading cause of dementia in patients under 65 years.

FTLD presents as several forms — behavioral FTLD is characterized by emotional deficits, impulsivity and a lack of empathy; semantic dementia is marked by a gradual loss of the meaning associated with words; and progressive non-fluent aphasia is impacts patients? production of language.

Patients with the behavioral form of the disease frequently exhibit unexpected artistic and musical talents that may initially intensify as the disease progresses, a phenomenon that Miller has documented. This trait is attributed to the strengthening and remodeling of parts of the brain linked to creativity, compensating for damaged areas associated with language.

When Miller started studying FTLD more than 25 years ago, the mantra in neurology was ?Don?t pick Pick?s disease,? he says. At the time, the disease was viewed as a ?rare, biologically obscure illness that could not be diagnosed at the bedside.?

Today, thanks in part to Miller and colleagues? pioneering research, neurologists are able to distinguish FTLD from Alzheimer?s disease in its earlier stage. Promising advances have been made in the genetics and molecular pathology of the disorder. Recent developments include testing therapies that target the genetic cause for FTLD, a milestone that Miller describes as ?the most exciting work? he has ever undertaken.

Author of the book ?The Human Frontal Lobes? and the medical director of the John Douglas French Foundation for Alzheimer?s Disease, Miller works closely with UCSF Nobel laureate Stanley Prusiner, MD, director of the UCSF Institute for Neurodegenerative Diseases and, himself, the 1991 recipient of the Potamkin Prize. In the early 2000s, they conducted a clinical trial using an experimental drug to treat the dementia known as Creutzfeldt-Jakob disease (CJD).

Prusiner won the Nobel Prize in Physiology or Medicine in 1997 for his discovery of prions, a class of proteins that causes CJD in humans and ?mad cow? disease in cattle. The discovery has informed research into the role of misprocessed proteins in more common brain diseases, including Alzheimer?s and Parkinson?s disease.

Mucke, a basic researcher, is best known for his role in instigating a turnaround in the direction of research into Alzheimer?s disease, from an almost exclusive focus on morphological abnormalities in the brain to a focus on the molecular processes that cause the dysfunction of neural networks in the brain.

Ten years ago, many scientists believed the condition was caused by the accumulation of amyloid plaques in the brain. Mucke and colleagues showed that a minuscule constituent of these plaques, known as amyloid-beta peptide, can disrupt the function of brain cells independent of plaques, thus narrowing the whereabouts of the disease culprit from the ?haystack? to the ?needle.?

Mucke has also generated genetically engineered mice to pinpoint the key molecules and proteins that contribute to the progression of Alzheimer?s thereby setting the stage for new therapies to combat the disease. Using mouse models of Alzheimer?s disease, Mucke and colleagues have successfully prevented the disease progression and even reversed cognitive impairments.

The Potamkin Prize, says Mucke, is a wonderful reinforcement of the synergism? between himself and Miller. ?Working hand-in-hand, we have developed innovative translational programs for the investigation and treatment of dementia and related disorders.?

Miller concurs, describing the Potamkin Prize as ?the highlight of my academic career.?

The Gladstone Institutes is a nonprofit, independent research and educational institution, consisting of the Gladstone Institute of Cardiovascular Disease, the Gladstone Institute of Virology and Immunology and the Gladstone Institute of Neurological Disease. Independent in its governance, finances and research programs, Gladstone shares a close affiliation with UCSF through its faculty, who hold joint UCSF appointments.

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.

Related Links:

Bruce Miller, UCSF Memory and Aging Center

http://tinyurl.com/yervum8

Lennart Mucke, Gladstone Institute for Neurological Disease

http://www.gladstone.ucsf.edu/gladstone/site/mucke/

UCSF Neuroscience Building to drive advances against brain diseases

http://news.ucsf.edu/releases/ucsf-neuroscience-building-to-drive-advances-against-brain-diseases/

Contact:

Jennifer O?Brien (415) 476-2557

E-mail:

Convincing Research Now Shows How Correct Moderate Exercise Can Add Ten Healthy Years To Your Life

Minneapolis, MN (PRWEB) March 5, 2010

Forrest Blanding, author of the informative new Cardiofitness Can Save Your Life (Bascom Hill Books; ISBN 978-1-935098-04-1; April 2009; $ 19.95) reveals from a ten-year scientific analysis of more than five hundred key research studies that regular and, more importantly, correct moderate exercise could add seven to ten healthy years to the life of an average fifty-year-old American.

Blanding notes “The number one key to a better and longer life is a measurable fitness of our heart and its cardiovascular system. Eighty-five percent of our health benefits from exercise derive from cardiofitness.”

Cardiofitness Can Save Your Life examines how many people today are wasting enormous amounts of time doing exercise that may produce only minimal benefit to their health. Cardiofitness does not develop simply from calories of exercise. Blanding says, “It develops best from just two hours per week or about seventeen minutes per day of certain levels of correct monitored exercises that most people can do comfortably.”

The author describes a new Cardio 120 program, and a new Cardio Point method that can show people how to develop the level of cardiofitness they need in order to obtain optimum health.

Blanding provides an easily understandable scientific measure of this cardiofitness (called the CFR which is a percentage of average for age and gender) and describes simple tests for measuring it. Blanding shows that better knowledge of CFR helps to decrease the risk of heart disease, cancer, diabetes, and even Alzheimer’s. You can even use the measuring tool online from the book’s website. It couldn’t be easier to measure your cardiofitness.

Cardiofitness Can Save Your Life is intended for a range of readers from health and fitness professionals and caregivers, to anyone looking for scientifically supported secrets to better health and a longer life.

Cardiofitness Can Save Your Life is available at through Ingram and Baker & Taylor and from the author’s website http://www.cardiofitnesshealth.com.

# # #





Scientists Report Key Finding in Breast Cancer Research


Philadelphia, PA (Vocus) April 17, 2010

Researchers at Drexel University College of Medicine have discovered that a certain type of sugar found naturally in the body is elevated in breast cancer cells and is critical for cancer growth and movement. When researchers reduced and normalized the levels of this sugar, they were able to slow the growth of the cancer cells and block invasion. The findings, published in the March 1 issue of Oncogene, represent a potential new therapeutic target for treating aggressive forms of breast cancer.

Scientists have known for years that cancer cells are addicted to sugar. Compared to neighboring normal cells, cancer cells take up nearly ten times more sugar. The cancer cells use the increased sugar levels to fuel rapid cell growth and spread. The Drexel researchers studied a particular sugar-based protein modification known as O-GlcNAc. Alterations in this modification have been linked previously to diabetes and Alzheimer?s disease, but not to cancer.

?This sugar, O-GlcNAc, is used inside cells to tag proteins and alter their function,? said lead author Mauricio J. Reginato, Ph.D., assistant professor in the Department of Biochemistry and Molecular Biology at Drexel University College of Medicine. ?We think this is a very exciting discovery because this may be one way that cancer cells use the increased sugar to regulate key pathways that control growth and invasion.?

Reginato and his colleagues studied established cells from patients with estrogen-independent breast cancer, the most aggressive form of the disease, which does not respond well to current treatments. The researchers found that compared to normal mammary cells, all the breast cancer cells contained elevated levels of O-GlcNAc, as well as increased levels of the enzyme responsible for adding this sugar to protein.

When they reduced the levels of the O-GlcNAc enzyme, or blocked its activity with a drug, they reduced the growth of breast cancer and also blocked the invasion. In addition, by reducing the enzyme levels, they also reduced levels of a protein known as FoxM1, which is known to play a critical role in controlling cancer growth and spread.

The Drexel researchers and collaborators are now working to develop more potent chemicals to target the O-GlcNAc enzyme, a potential new therapeutic target for treating breast cancer and possibly other cancers.

?We looked at cancer databases and found that this enzyme is also elevated in other types of cancers.? said Reginato. ?Our next step will be to study those cancers more closely to determine if we can achieve the same effect.?

About Drexel University College of Medicine

Drexel University College of Medicine has established some of the most highly innovative and rigorous academic programs available today, incorporating the University?s expertise in engineering and technology into traditional medical training. The College of Medicine is home to one of the nation?s leading centers for spinal cord research; one of the foremost centers for malaria study; and a highly regarded HIV/AIDS program with extensive NIH-funded research in prevention and therapeutic interventions. Drexel University College of Medicine has been designated a Vanguard National Center of Excellence in Women?s Health by the U.S. Department of Health & Human Services, and is highly respected in numerous other specialties including autism, cardiology, minimally invasive surgery, and toxicology. Visit http://www.drexelmed.edu for more information.

Media Contact:

Rachel Sparrow,

215-255-7328

###





Find More Alzheimer Disease Press Releases

Quincy Bioscience Launches HOPETrials.com; Research Studies More Accessible For Participants


Madison, WI (Vocus) May 14, 2010

Quincy Bioscience announces the launch of HOPE Trials.com ? a new portal aimed at making research studies of the jellyfish protein apoaequorin accessible for individuals with debilitating conditions. HOPE Trials is the research arm of Quincy Bioscience.

The mission of HOPE Trials is to improve the quality of life for individuals suffering from an array of debilitating conditions such as Alzheimer?s disease and Parkinson?s disease linked by a common cause ? a mismanagement of calcium at the cellular level. By bringing research studies into the homes of individuals living with neurodegenerative diseases, researchers are able to achieve larger numbers of participants and improve the quality of data gathered.

Quincy Bioscience research to date has shown the effectiveness of the jellyfish protein apoaequorin to improve cognitive function and other quality of life measures in generally healthy individuals. With the development of the HOPE Trials website and the implementation of clinically-validated rating scales, researchers at Quincy Bioscience will be able to gain better understanding on how this jellyfish protein may help improve the lives of those with neurological conditions.

Mark Underwood, co-founder and president, stresses the importance of both high quality and real world research, ?HOPE Trials represents an innovation in research by delivering survey tools directly to participants. Two of the main reasons people choose not to take part in conventional clinical studies are the amount time and travel required. HOPE Trials greatly reduces these demands while gathering important data using the gold standard in research, randomized controlled trials.? explains Underwood.

Maximizing the use of the Internet and social media to help recruitment, HOPE Trials will access a larger demographic of people, and strengthen research. HOPE Trials has begun recruiting for the MS HOPE Trial. Interested parties can visit HOPE Trials.com to find out if they qualify to participate and learn more about future studies.

About Quincy Bioscience

Quincy Bioscience is a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the aging process. The company’s products focus on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms.

# # #





More Alzheimer Disease Press Releases

Asia Research News 2010


(PRWeb UK) June 25, 2010

We are pleased to announce that the annual publication Asia Research News 2010 is now available online at Asia Research News

The magazine features interesting on-going research from selected Asian universities in the fields of:

Agriculture

Aquaculture

Biotechnology

Culture

Environment

Food

Health and medicine

Health technology

International relations

Language

Literature

Technology

A small number of printed copies are available for journalists, universities and research institutions. If you would like a printed copy of the magazine please get in touch with us by email to Magdeline Pokar m.pokar(at)researchsea(dot)com, telephone +44 (0)1954 261958 or fax +44 (0)8706220887.

We hope you will enjoy reading the magazine and welcome your feedback.

About ResearchSEA – ResearchSEA connects journalists and members of the public to news and experts from the research world in Asia. Registration is free. Journalists have additional access to embargoed press releases and contact details of experts. For more information about ResearchSEA, please go to our website ResearchSEA

The articles in Asia Research News 2010 are:

AGRICULTURE

A cherry tree for all seasons

Buffalo vaccine

Torch ginger

Improving oil-palm kernel

Controlling ammonia in poultry farms

Pea aphid and soybean genome sequenced

The proteins that help plants keep time

Organic fungicide from agriculture waste

Healthy food

Precision farming

Wood machining doctor

Determining orchid colours

AQUACULTURE

Supporting fishing communities

Sustaining seafood

Culturing horseshoe crabs

TECHNOLOGY

Nano-aquarium opens up a new realm of research

Faster, more accurate drawing

Using physics to help queues

Unlocking the power of wood

Blast from the past

Children and computers

All sky x-ray image data online

Mobile phones creating choices for farmers

A new antenna

New base for Telecentre in the Philippines

Sensitive hybrid

Clean energy

Mobile video on demand

Reducing interference in RFID readers

Counting down to the brightest light…

Music-friendly information retrieval

Enhancing underwater video

Monitoring landslide and flood risk

Minimising knowledge loss

High-performance varistor

Next-Generation Supercomputer

Cross platform enterprise security

LANGUAGE

The origin of language

Iban alphabet now in computer fonts

Anthology of Southeast Asian Literature in English

Impact of new technology on language

Creating a universal playground

Focusing on Filipino language

ENVIRONMENT

Orchid diversity

Terrestrial carbon sequestration

Degradable polymer

Wooden alternatives

Transforming carbon dioxide into methanol

Indigenous fibre for car bumpers

Environmental CoaTIN technology

Detecting and cleaning oil spills

Reducing pollution in Jakarta slums

Monitoring and cleaning contaminants

SOCIETY

Lifestyle China

Promoting an active life

Spiritual intelligence

A satisfied society

Ethnographic profiling in metro Manila

Influences on cultural identity

Oldest civilisation in Southeast Asia

Researching poverty in China

The Deep South

Promoting community governance

Career profiling

Research consortium for theatre and film arts

Predicting tourists? future behaviour

The Philippine music hybridity project

18th and 19th century Philippines

HEALTH AND MEDICINE

Understanding and treating cancer

Diabetes

Improving the health of astronauts

Brain change

Diagnosing amebiasis

Identifying gelatine in pharmaceuticals

Controlled drug delivery

New vaccine for childhood illness

Sights set on immunisation target

Nanotechnology combats fatal brain infections

Novel nanobiocomposites

Elucidating Alzheimer’s genes

Tackling the onset of Down syndrome

Toothbrush from a twig

Milking the Milkfish

Carpal tunnel treatment

Japanese genomes and ulcerative colitis

Asian research into emerging infectious diseases

HEALTH TECHNOLOGY

A new era of pressure management in medicine

Thai-English Braille computer notebook

Reducing the cost of DNA diagnostics

Measuring skull and face

Care bear robot

Wheelchair technology

Lightweight gamma camera

Medical imaging also helps electronics industry

The knee motion assistive system

Ultrasound diagnosis for breast cancer

###





Related Alzheimer Disease Press Releases

The Pioneer Fund Contributes $1.5 Million Gift To The Brain Research Foundation For Atypical Dementia Research

Chicago, Illinois (PRWEB) October 7, 2010

The Brain Research Foundation (BRF) and The Pioneer Fund today announced a $ 1.5 million endowment to study atypical dementia. ?The Pioneer Fund?s generous contribution ensures substantial research will continue to advance the understanding of atypical dementia,? said BRF Executive Director Terre A. Sharma, Ph.D. ?The funding of this endowment comes at a critical time and means that the tremendous potential of early stage research will continue to be explored.?

Atypical dementias are unusual cases of dementia related to a variety of underlying pathologies, including atypical Alzheimer?s disease, frontotemporal dementia, dementia with Lewy bodies, and prion disease, among others. Because these types of cases are not as common, research has not pursued them as vigorously as typical dementia. However, much can be learned from these less common conditions that could benefit people suffering from both typical and atypical dementia.

A private family foundation, The Pioneer Fund was established by Helen M. McLoraine and her mother, Mabel Green Myers, in 1962. The Fund was created to support medical research, higher education scholarship assistance, and youth social welfare. ?We are very encouraged by the innovative work that the Brain Research Foundation supports and are confident that our grant will serve to further the understanding of atypical dementia,? stated a representative of the Pioneer Fund.

In 2006, Dr. Lawrence Pottenger, a University of Chicago orthopedic surgeon and Ms. McLoraine?s cousin, died as a result of complications due to early onset Alzheimer?s disease. His wife was instrumental in connecting the Brain Research Foundation with The Pioneer Fund to create this endowment to research atypical dementia. This work will be led by Dr. James Mastrianni, Associate Professor of Neurology at the University of Chicago, who was Dr. Pottenger?s doctor.

About the Brain Research Foundation

The Brain Research Foundation funds innovative neuroscience research that expands understanding of how the brain works, and provides educational programs for researchers, families struggling with debilitating brain disorders and the general public. The Foundation plays a critical role in the scientific process by funding seed grants that are the starting blocks to discovery, allowing scientists to prove the feasibility of their projects and produce data that will make them eligible for larger government and institutional funds.

# # #





enGrant Scientific Launches Site for Tracking Scientific Research and Grant Funding


Houston, TX (PRWEB) November 30, 2010

enGrant Scientific, a publisher of information on scientific research activity and funding trends launches the GrantScape

Alzheimer’s Disease – Diagnosis, Research, Support

San Francisco, CA (PRWEB) October 9, 2009

With projections forecasting drastic increases in the number of people expected to have Alzheimer’s, now more than ever is the time to become involved through diagnosis, research and support. The Alzheimer’s Association states that an average of 11,000 Californians will develop Alzheimer’s each year. In fact, the Alzheimer’s Association’s 2009 report indicates that by 2030 Californians of Hispanic, Asian and Pacific Islander descent with Alzheimer’s Disease will triple and African Americans and Caucasians will double. Eldercare Services has the honor and privilege to guide and coach many families dealing with dementia. This is in part, why they are committed to the fight against Alzheimer’s Disease.

Getting a good diagnosis is important, but where do families or individuals begin when they suspect something is wrong with their memory or that of a family member? The first step is to have a memory screening. The results of that will warrant either further diagnostic testing or reassure the individuals that he or she is in the “normal” range and need not worry. There are multiple reasons we have memory glitches – it’s not always a progressive disease like Alzheimer’s so screening is vitally important.

Eldercare Services will be participating in the Alzheimer’s Foundation of America’s National Memory Screening Day on Tuesday, November 17th. They will provide free confidential memory screenings at their Walnut Creek office located at 1808 Tice Valley Blvd., between 9:00 AM and 4:00 PM and their San Francisco office at 605 A Chenery Street, between 10:00 AM and 3:00 PM. Appointments are available and can be made by calling toll free at (866) 760-1808.

Finding a cure for the disease is something everyone hopes and prays for – however, those who conduct research require funding. Eldercare Services is proud to support the Bay Area’s local Alzheimer’s Association during the annual Memory Walk on Treasure Island on Saturday, October 10th. Those interested in joining the team on the walk or donating, can do so by visiting Eldercare Services’ special Memory Walk website at http://tinyurl.com/ECSMemoryWalk.

Participating in clinical research trials is another way to help the scientific community find medications that can stop the disease or extend the functioning level of those with this diagnosis. Eldercare Services is partnering with CARE-PAC, a program helping elders participate in advancing research on Alzheimer’s Disease. Currently, a pre-screening of potential candidates for clinical trials in Berkeley and San Francisco is under way. If interested in being considered for this research, contact Vivian Torres, RN, LCSW, at Eldercare Services to inquire about a confidential phone screening to determine eligibility.

Supporting Alzheimer’s family caregivers is one of Eldercare Services’ core values – the informed family means better care for everyone. Please note that Eldercare Services offers complimentary monthly support groups and a series of 3 classes specifically designed for those caring for someone with a dementia. These no-fee classes fill quickly, so call in advance to reserve space. To view their full listing of support groups, class topics and dates please call or visit our website at http://www.EldercareAnswers.com.

The next class, Dementia- Middle of the Road, will be held this Tuesday, October 13th from 6:00 PM to 8:00 PM at the Walnut Creek office. This class will cover the path of Alzheimer’s Disease, skills to preserve dignity, understanding and managing stress and letting go of guilt and anxiety. Class participants will feel more prepared validated and free to find balance in their lives.

Alzheimer’s disease is on the rise, but so is dedication to diagnosis, research and support. Please pass this information on to someone you care for, serve or love. Together we can make a difference.

About Eldercare Services:

Linda Fordini-Johnson, MA, MFT, CMC, is the Founder and Executive Director of Eldercare Services and President-Elect of the National Association of Professional Geriatric Care Managers. Eldercare Services is a pioneer in a unique delivery of services, providing counseling, geriatric care management, family support groups, classes and direct Caregiving with offices in Walnut Creek, Marin, Oakland and San Francisco, California.

Contact:

Beryl Anderson, Marketing and Public Relations Coordinator

Eldercare Services

(866) 760-1808

http://www.EldercareAnswers.com

###





Related Alzheimer Disease Press Releases

Clin360 Set to Change the Medical Research Study Game Permanently


Lasne, Belgium (PRWEB) October 21, 2011

The days of slow, disorganized clinical trials and isolated silos of information are finally over. clin360 is a new content management system (CMS) for the healthcare market that will forever change the way we carry out and even think about clinical trials. The pharmaceutical industry, research organizations, and healthcare professionals alike are sure to appreciate the convenience and flexibility of this ingenious platform, which acts as a central hub for sites, doctors, CRAs, and anybody else involved ? or even merely interested ? in any particular trial. And more importantly, vital clinical trials involving potentially life-saving technology will proceed on a more timely basis.

clin360 is described in a dedicated website: http://www.clin360.com. For those who visit the site and decide to get hooked up, the great benefits of such a well-thought-out CMS will be immediately evident. Users are going to get a platform which takes all aspects of running a clinical trial and brings them together under one format, making it easily and securely available to anyone involved anywhere in the world, using any type of standard browser. CRAs, investigators, health care professionals, management, and the public alike are going to love the control, visibility and overall access.

In designing this product, the internationally recognized Coligane Group set out with the goals of making trial recruitment easier, and streamlining the monitoring and management of trials by CRAs. Public access to trial progress and general information was another major consideration in its overall design. ?We feel that public education about clinical trials, and streamlining the efficiency of those trials, not only ought to be a moral imperative, but that it really just makes good business sense,? says Olivier Laurent, CEO at Coligane. He explains: ?Getting the public excited about pure research, product development, and/or possible distribution is one of the best marketing strategies out there ? not merely for the subject of your trial, but for your entire brand or institution.?

But, good PR aside, the primary crux of clin360 lies in the process itself. Every aspect of clin360 has been thoroughly tested by seasoned industry professionals, and all of them attest to both the usability and the security of the system. The platform features 5 different levels of secure access: HCP, Investigator, CRA, Manager, and Administrator. Each user has the ability to custom configure the settings in order to prioritize different sources of information, as well as to disseminate info to appropriate parties. The platform offers SMTP services (e-mail) and hosting, Google analytics activation for HCP, Investigator, Manager and CRA role users, allows multiple languages within its context, and is designed to be user friendly, practical, and useful to practically every member of the study team.

Having developed such a novel, convenient, and innovative product, Coligane is clearly targeting the entire world market. ?Luxembourg has been the first to take on the platform, even before the official launch, but we?re shooting for all corners of the globe?, says Laurent. He continues, ?Our position as a consultancy allows us superior flexibility in both thought and action. For instance, Coligane group will install and configure this core CMS onto our clients? own servers, or we can propose a dedicated hosting plan on our very own data center. We are able to adapt clin360 to each client?s needs, for each and every unique situation.? Coligane seems to have its ducks in a row with clin360? an instantly essential and desirable product, a well-planned marketing strategy, and the prestige of a respected, well-connected research consultancy group will go a long way to ensure great success.

About Coligane Group

Coligane Group is an entrepreneurial consultancy based in Lasne Belgium, specializing in Health Care, Pharmaceutical, and Clinical Research solutions, as well as the Computer and Service Industries in general. Coligane takes a full-spectrum approach to their services, acting as a solid platform for their clients, helping their dreams develop quickly into concrete applications

Follow coligane @coligane

Clin360 on Facebook Like here

###





Related Wellness Press Releases